tiprankstipranks
Pharming Group (PHAR)
NASDAQ:PHAR
US Market

Pharming Group (PHAR) Income Statement

Compare
119 Followers

Pharming Group Income Statement

Last quarter (Q3 2024), Pharming Group's total revenue was €75.06M, an increase of 12.60% from the same quarter last year. In Q3, Pharming Group's net income was €-1.03M. See Pharming Group’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
€ 245.32M€ 205.62M€ 189.85M€ 228.39M€ 189.33M
Gross Profit
€ 220.10M€ 188.06M€ 169.67M€ 203.06M€ 165.41M
Operating Expenses
€ 225.49M€ 169.83M€ 156.72M€ 120.97M€ 97.19M
Depreciation and Amortization
€ 15.93M€ 13.19M€ 19.61M€ 8.31M€ 5.80M
EBITDA
€ 9.88M€ 33.53M€ 48.78M€ 92.11M€ 71.46M
Operating Income
€ -4.88M€ 18.23M€ 27.84M€ 82.09M€ 68.23M
Other Income/Expenses
€ -7.13M€ -3.25M€ -4.76M€ -18.33M€ -15.94M
Pretax Income
€ -12.01M€ 14.99M€ 22.03M€ 47.47M€ 52.29M
Net Income
€ -10.55M€ 13.67M€ 16.00M€ 37.75M€ 40.54M
Per Share Metrics
€ ―€ ―€ ―€ ―€ ―
Basic EPS
€ -0.01€ 0.21€ 0.25€ 0.58€ 0.65
Diluted EPS
€ -0.01€ 0.19€ 0.23€ 0.55€ 0.60
Weighted Average Shares Outstanding
657.03M 70.71M 70.12M 68.27M 67.35M
Weighted Average Shares Outstanding (Diluted)
657.02M 70.71M 70.12M 68.27M 67.35M
Currency in EUR

Pharming Group Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis